CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference

Arizona Tribune - CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference

CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference

– Video webcast now available on-demand

Text size:

HOUSTON, TX / ACCESS Newswire / July 22, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.

As part of the event, Mr. Climaco dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development.

The on-demand video webcast is now available on virtualinvestorco.com as well as the Events page of the Investors section of the Company's website (cnspharma.com).

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.

The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, progressive neoplastic disease, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears to have both an excellent safety profile and high tolerability among patients.

For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.

CONTACTS:

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]

SOURCE: CNS Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

K.Hill--AT

RBGPF	-0.45%	60.34	$
CMSC	-0.95%	22.16	$
CMSD	-0.95%	22.08	$
RIO	-0.72%	99.36	$
BCC	-2.92%	72.54	$
BP	1.71%	39.78	$
BTI	-0.02%	58.9	$
NGG	1.89%	80.97	$
BCE	-2.78%	22.65	$
GSK	0.14%	50.74	$
RYCEF	1.23%	18.63	$
JRI	-0.16%	12.65	$
RELX	-1.14%	30.83	$
AZN	0.85%	176.43	$
VOD	-1.27%	14.12	$

Arizona Tribune - CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference

CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference

Featured

Kenya police violence victims say compensation promise a 'smokescreen'

North America LiberNovo Prime Sale Fully Launches June 23

InterContinental Hotels Group PLC Announces Transaction in Own Shares - June 23

Who Is Really Influencing Trump Marijuana Rescheduling?